EOLS
Evolus, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 651.82K | $5.21M | n/a | n/a |
| Q2 2026 | 63 | +6 | 23.25M | $161.16M | +10 | −4 |
| Q1 2026 | 59 | -7 | 18.93M | $77.97M | +3 | −10 |
| Q4 2025 | 66 | -1 | 24.04M | $159.85M | n/a | −1 |
| Q3 2025 | 17 | -1 | 17.27M | $106.03M | n/a | −1 |
| Q2 2025 | 15 | 0 | 14.12M | $130.04M | +1 | −1 |
| Q1 2025 | 12 | +2 | 7.19M | $86.49M | +2 | n/a |
| Q4 2024 | 10 | -1 | 6.42M | $70.90M | n/a | −1 |
| Q3 2024 | 10 | 0 | 4.64M | $75.21M | +1 | −1 |
| Q2 2024 | 10 | n/a | 4.38M | $47.51M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.20M | n/a | $13.02M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Millennium Management ✦ | 899.38K | n/a | $9.76M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | D. E. Shaw & Co. ✦ | 871.10K | n/a | $9.45M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Soros Fund Management ✦ | 850.00K | n/a | $9.22M | 0.3% | n/c | 1 | SEC ↗ |
| 5 | Marshall Wace ✦ | 201.85K | n/a | $2.19M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 134.32K | n/a | $1.46M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | AQR Capital Management ✦ | 72.01K | n/a | $781,276 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 8 | Citadel Advisors ✦ | 64.12K | n/a | $695,659 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 45.61K | n/a | $495,000 | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 40.70K | n/a | $441,595 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 146 holders, 45.63M shares, $187.01M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 105.11K sh · $950,019
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology